Stablecoin Development Corp
3 nominees · 11 ballot items.
Election of three Class III directors; Say-on-Pay; Say-on-Frequency; ratification of the independent registered public accounting firm; NYSE American approval for issuance of common stock upon conversion of Series D and Series E; increase in shares available under the 2017 Omnibus Plan; Equity Consideration to resigning non‑employee directors; reverse stock split; increase in authorized common stock; increase in authorized preferred stock; and adjournment of the Annual Meeting.
Follow how the vote landed and what changed on Stablecoin Development Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot11
- 1
Election of Class III Directors
ManagementBoard: FORElection of Dr. Paul E. Freiman, David E. Lazar and Swan Sit to three-year terms on NovaBay’s Board.
- 2
Advisory, Non-Binding Vote to Approve Executive Compensation (Say-on-Pay
ManagementBoard: FORAdvisory vote on the compensation of NovaBay’s named executive officers, as disclosed in the Proxy Statement.
- 3
Advisory, Non-Binding Vote on the Frequency of Say-on-Pay
ManagementBoard: FORAdvisory vote on how often NovaBay stockholders want Say-on-Pay votes (every 1, 2, or 3 years).
- 4
Advisory, Non-Binding Vote to Ratify the Selection of the Independent Registered Public Accounting Firm
ManagementBoard: FORRatification of WithumSmith+Brown, PC as NovaBay’s independent registered public accounting firm for the 2025 fiscal year.
- 5
Approval of Issuance of Common Stock Upon Conversion of Series D Preferred Stock and Series E Preferred Stock (NYSE American Proposal
ManagementBoard: FORStockholder approval to issue up to 120,000,000 shares of Common Stock upon conversion of the Series D and Series E Preferred Stock (to be issued in the Final Closing), as required by the NYSE American Company Guide.
- 6
Approval to Increase Shares Available for Issuance Under the 2017 Omnibus Plan
ManagementBoard: FORIncrease the number of authorized shares under the 2017 Omnibus Plan by 1,000,000, with corresponding changes to grant limits.
- 7
Approval of the Equity Consideration to Resigning Non-Employee Directors
ManagementBoard: FORApproval of the Equity Consideration, comprised of newly-issued restricted Common Stock with an aggregate value of $40,000, to each resigning non-employee director.
- 8
The Reverse Stock Split Proposal
ManagementBoard: FORApprove a reverse stock split of not less than 1-for-2 and not more than 1-for-10, with Board discretion to set the ratio and timing.
- 9
Approval to Increase Authorized Common Stock
ManagementBoard: FORIncrease the authorized Common Stock from 150,000,000 to 1,500,000,000 shares.
- 10
Approval to Increase Authorized Preferred Stock
ManagementBoard: FORIncrease the authorized preferred stock from 5,000,000 to 10,000,000 shares.
- 11
The Adjournment Proposal
ManagementBoard: FORGrant discretionary authority to the Board to adjourn the Annual Meeting to secure votes if necessary.
Nominees on the ballot3
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 0.7% | 366,770 | $385K |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 0.6% | 326,988 | $343K |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 0.4% | 226,186 | $238K |
| 4 | VANGUARD FIDUCIARY TRUST CO | 0.3% | 131,840 | $138K |
| 5 | STATE STREET CORP | 0.2% | 117,154 | $123K |
| 6 | NORTHERN TRUST CORP | 0.1% | 59,926 | $63K |
| 7 | BlackRock, Inc. | 0.1% | 57,925 | $61K |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.1% | 55,297 | $58K |
| 9 | Bank of New York Mellon Corp | 0.1% | 28,032 | $29K |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 0.1% | 26,142 | $27K |
Other Healthcare sector meetings6
Upcoming shareholder meetings at Stablecoin Development Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Stablecoin Development Corp 2025 annual meeting?
- Stablecoin Development Corp (SDEV) holds its 2025 annual shareholder meeting on Thursday, October 16, 2025.
- What is the record date for the Stablecoin Development Corp 2025 meeting?
- The record date for the Stablecoin Development Corp 2025 meeting is Monday, September 22, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Stablecoin Development Corp's 2025 meeting?
- The board is presenting 3 director nominees at the Stablecoin Development Corp 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Stablecoin Development Corp 2025 meeting?
- Shareholders will vote on 11 proposals at the Stablecoin Development Corp 2025 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.